Acta paediatrica (Oslo, Norway : 1992) · 2025
Neurodevelopment and Growth 2 Years After Probiotic Supplementation in Extremely Preterm Infants: A Randomised Trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wejryd Erik, Marchini Giovanna, Bang Peter, Jonsson Baldvin, Ådén Ulrika, Abrahamsson Thomas
Аннотация
AIM: To assess neurodevelopment and growth at 2 years corrected age in children born extremely preterm, supplemented with Limosilactobacillus reuteri or placebo.
METHODS: Design: Secondary analysis of register data after randomised double-blind placebo-controlled trial.
SETTING: Inclusion at two neonatal intensive care units in Sweden. Local follow-up per national guidelines.
SUBJECTS: 134 infants born at 23-27 weeks' gestation with a birth weight < 1000 g.
INTERVENTION: Daily enteral supplementation with placebo or Limosilactobacillus reuteri DSM 17938 (2.5 × 108 colony forming units), from within 72 h after birth to postmenstrual week 35-36.
MAIN OUTCOME MEASURES: Bayley-III developmental assessment and auxology at 24 ± 3 months corrected age.
RESULTS: Follow-up data were available for 110 of 117 surviving participants, and 85 children were assessed with Bayley-III. Mean language score after supplementation with L. reuteri was 90 (95% confidence interval: 85-95) compared to 83 in the placebo group (95% CI: 78-88), p = 0.04. No other significant differences in neurodevelopment or growth were observed.
CONCLUSION: Supplementation with L. reuteri in extremely preterm infants was not associated with altered growth nor general neurodevelopmental outcomes at 2 years while language index was improved. This is interesting given previously reported early improved growth of head circumference.
METHODS: Design: Secondary analysis of register data after randomised double-blind placebo-controlled trial.
SETTING: Inclusion at two neonatal intensive care units in Sweden. Local follow-up per national guidelines.
SUBJECTS: 134 infants born at 23-27 weeks' gestation with a birth weight < 1000 g.
INTERVENTION: Daily enteral supplementation with placebo or Limosilactobacillus reuteri DSM 17938 (2.5 × 108 colony forming units), from within 72 h after birth to postmenstrual week 35-36.
MAIN OUTCOME MEASURES: Bayley-III developmental assessment and auxology at 24 ± 3 months corrected age.
RESULTS: Follow-up data were available for 110 of 117 surviving participants, and 85 children were assessed with Bayley-III. Mean language score after supplementation with L. reuteri was 90 (95% confidence interval: 85-95) compared to 83 in the placebo group (95% CI: 78-88), p = 0.04. No other significant differences in neurodevelopment or growth were observed.
CONCLUSION: Supplementation with L. reuteri in extremely preterm infants was not associated with altered growth nor general neurodevelopmental outcomes at 2 years while language index was improved. This is interesting given previously reported early improved growth of head circumference.